(Q37620841)

21 August 2017

1 reference

title

Trial design for evaluation of novel targeted therapies (English)

1 reference

21 August 2017

John Farley

1

1 reference

21 August 2017

Peter G Rose

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

24 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

116

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

173-176

1 reference

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Novel designs and end points for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Alternate endpoints for screening phase II studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Sorafenib in advanced hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Considerations for the use of imaging tools for phase II treatment trials in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Radiologic measurements of tumor response to treatment: practical approaches and limitations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Optimising the design of phase II oncology trials: the importance of randomisation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Phase II trials in journal of clinical oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Randomized phase II designs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Randomized discontinuation design: application to cytostatic antineoplastic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Effective incorporation of biomarkers into phase II trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

The lessons of GIST--PET and PET/CT: a new paradigm for imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.046

10.1016/J.YGYNO.2009.09.046

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference